At the heart of this publication, entitled “A Robust, High-Titer, Semi-Automated, and In-Culture Antibody-Capturing Transient CHO Platform Technology” and co-authored by Pfizer, Magellan Biologics, and ExcellGene, is our CHO 4Tx® system – a high-yield, seamless transient CHO platform developed by Magellan Biologics and ExcellGene.
The study demonstrates how CHO 4Tx® delivered exceptional performance as the foundation of a semi-automated antibody-production workflow developed and validated at Pfizer, achieving:
- Consistent antibody titers above 200 mg/L (well above the current industry standards), even with challenging constructs – Excellent reproducibility and cell robustness
- A streamlined, scalable workflow naturally compatible with automation
This publication reinforces CHO 4Tx® as a next-generation transient expression system—combining performance with seamless usability—and confirms its value in bridging the gap between discovery and development.
*Gebhardt, L.; Abel, M.; Zhou, J.; Vogt, A.M.; Shin, B.H.; Herrick Wagman, S.L.; Santos, A.; Puginier, J.; Wurm, F.M.; Wurm, M.J.; et
al. A Robust, High-Titer, Semi-Automated, and In-Culture Antibody-Capturing Transient CHO Platform Technology. Antibodies 2025, 14, 87. https://doi.org/10.3390/antib14040087
US Patent N° US 11,746,360 B2
